Digestive Disease Week

Digestive Disease Week

May 02, 2020
1 min watch
Save

VIDEO: Trulance improves pain in chronic idiopathic constipation, IBS-C

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Gregory Sayuk, MD, MPH, from the division of gastroenterology at Washington University School of Medicine in St. Louis discusses his poster from Digestive Disease Week on four randomized trials that explored the efficacy of Trulance in patients with chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.

In the trials, researchers randomly assigned patients to receive 3 mg or 6 mg of Trulance (plecanatide, Salix) or placebo for 12 weeks. Patients recorded daily abdominal pain symptoms at baseline, at the end of 12 weeks of treatment and in a 2-week period after treatment.

For both CIC and IBS-C, the plecanatide groups had greater reductions in weekly mean abdominal pain scores compared with the placebo groups.

Reference:

Bharucha AE, et al. Plecanatide for Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome Constipation: Analysis of Abdominal Pain from Four Randomized Phase 3 Clinical Trials. Digestive Disease Week; May 2-5 2020 (meeting canceled).

Disclosures: Sayuk reports consulting and speaking for Allergan/Ironwood and Salix, as well as consulting for the GI Health Foundation.